Breaking Finance News

Sierra Oncology (NDAQ:SRRA) has been upgraded from Hold to Buy in a report by Jefferies & Co today.

Yesterday Sierra Oncology (NDAQ:SRRA) traded 7.93% higher at $1.77. The company’s 50-day moving average is $1.64 and its 200-day moving average is $1.41. The last stock close price is up 25.48% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 191,953 shares of the stock were exchanged, down from an average trading volume of 293,131

Jefferies & Co has upgraded Sierra Oncology (NDAQ:SRRA) from Hold to Buy in a report released on 10/23/2017.

See Chart Below

Sierra Oncology (NDAQ:SRRA)

Sierra Oncology has a 52 week low of $1.10 and a 52 week high of $1.94 SRRA’s total market value is presently $0.

Brief Synopsis About Sierra Oncology (NDAQ:SRRA)

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company's lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company's SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.